A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Ozempic, known generically as semaglutide, is an injectable prescription drug. It was approved in 2017 by the United States ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...